Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.46 |
| ▸ | UMPS | P11172 | 5/20 | 0.45 |
| ▸ | ATIC | P31939 | 2/20 | 0.45 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.45 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | GART | P22102 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31685597 | 0.83 | ADORA1 (0.37) | — | |
| SCHEMBL31685486 | 0.82 | CDA (0.47) | — | |
| SCHEMBL31685484 | 0.81 | TYMS (0.48) | — | |
| SCHEMBL11178912 | 0.75 | HPRT1 (0.53) | FBP1UMPSATICDNPH1HPRT1 | |
| SCHEMBL1364683 | 0.74 | FBP1 (0.50) | FBP1UMPSATICDNPH1HPRT1 | |
| SCHEMBL19370845 | 0.74 | FBP1 (0.50) | FBP1UMPSATICDNPH1HPRT1 | |
| SCHEMBL7269691 | 0.74 | FBP1 (0.50) | FBP1UMPSATICDNPH1HPRT1 | |
| SCHEMBL11406434 | 0.74 | UMPS (0.50) | FBP1UMPSATICDNPH1HPRT1 | |
| SCHEMBL11406428 | 0.74 | UMPS (0.50) | FBP1UMPSATICDNPH1HPRT1 | |
| SCHEMBL31685585 | 0.72 | LGALS8 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | FBP1 3865/4885UMPS 770/4885ATIC 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.